Melodia Therapeutics has acquired the exclusive rights to develop, manufacture, and commercialize MDI-0151, a candidate therapy for hard-to-treat…
Articles by Patricia Inacio, PhD
Sinonasal manifestations — those encompassing the nose and the paranasal sinuses, or the air-filled cavities around the nose — in…
AstraZeneca’s Fasenra (benralizumab), which is approved for a rare type of asthma, led to clinical remission in up to…
A Phase 1 clinical trial evaluating the safety and preliminary efficacy of Sana Biotechnology’s candidate CAR T-cell therapy SC291…
Lower blood counts of platelets — tiny cell fragments involved in blood clotting — at the time that ANCA-associated…
Men with ANCA-associated vasculitis (AAV) are three times more likely to develop cancer, most often that affecting the lungs…
Undergoing plasma exchange or low-dose glucocorticoid therapy did not affect the risk of relapse in people with ANCA-associated vasculitis…
Two blood parameters — interleukin 8 (IL-8) and the neutrophil/lymphocyte ratio (NLR) — may help identify ANCA-associated vasculitis (AAV)…
Most people with ANCA-associated vasculitis (AAV) experience acute or chronic kidney injury, according to a five-year national study in the…
Long-term treatment with benralizumab — sold as Fasenra for a rare type of asthma — safely leads to clinical…